Décrire les caractéristiques cliniques des patientes atteintes d'un cancer de l'endomètre

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

Objectif principal
To describe the clinical outcomes of patients with metastatic Pole E mutated endometrial cancers

Objectifs secondaires
a) Description of clinico pathological characteristics of POLE E mutated patients, including TP53 status, expression of hormone receptors, tumour grade and MMRd status.
b) Proportion of patients with partial response (PR) or complete response (CR) among patients treated with platinum-based first line chemotherapy
c) Proportion of patients with PR or CR among patients treated with ICI based therapy
d) PFS of patients for the different therapies (platinum-based chemotherapy; ICI based-therapy; Endocrine therapy if applicable)
e) Overall survival (OS) of patients for the different therapies (platinum-based chemotherapy; ICI based-therapy; Endocrine therapy if applicable). OS is defined as the time from first line treatment start to the date of death from any cause; Patients alive will be censored at the date of last follow-up.
f) Proportion of de novo vs. recurrent patients and evaluation of the response to therapy accordingly
g) Depending on the number of patients, descriptive analyses for subpopulations will be completed by comparative analyses (exploratory).